SCHEMBL7940524

SCHEMBL7940524

CSc1ccc(C(=O)Nc2ccc(F)c(CNc3cccnc3N)c2)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 7/20 0.50
HDAC4 P56524 4/20 0.39
HDAC3 O15379 3/20 0.39
ABL1 P00519 3/20 0.39
PDGFRB P09619 3/20 0.39
KDR P35968 3/20 0.39
HDAC1 Q13547 3/20 0.39
HDAC7 Q8WUI4 3/20 0.39
HDAC2 Q92769 3/20 0.39
HDAC10 Q969S8 3/20 0.39
HDAC11 Q96DB2 3/20 0.39
HDAC8 Q9BY41 3/20 0.39
HDAC6 Q9UBN7 3/20 0.39
HDAC9 Q9UKV0 3/20 0.39
HDAC5 Q9UQL6 3/20 0.39
KMT2A Q03164 1/20 0.38
AURKA O14965 1/20 0.38
AURKB Q96GD4 1/20 0.38
PDPK1 O15530 4/20 0.37
GRM4 Q14833 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7944905 0.88 BACE1 (0.43) BACE1HDAC4HDAC3ABL1PDGFRB
SCHEMBL7943395 0.87 BACE1 (0.48) BACE1HDAC4HDAC3ABL1PDGFRB
SCHEMBL7942027 0.84 BACE1 (0.58) BACE1HDAC4HDAC3ABL1PDGFRB
SCHEMBL7935774 0.84 BACE1 (0.43) BACE1HDAC4HDAC3ABL1PDGFRB
SCHEMBL7946719 0.82 BACE1 (0.43) BACE1HDAC4HDAC3ABL1PDGFRB
SCHEMBL12302316 0.82 RAB9A (0.42) BACE1KMT2AAURKAAURKBALDH1A1
SCHEMBL7933218 0.81 BACE1 (0.50) BACE1HDAC3HDAC1HDAC8KMT2A
SCHEMBL7940454 0.81 HDAC2 (0.46) BACE1PDGFRBKDRHDAC1HDAC2
SCHEMBL7945376 0.80 BACE1 (0.54) BACE1NPC1RAB9A
SCHEMBL7941994 0.80 GAA (0.42) BACE1HDAC4HDAC3PDGFRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885HDAC4 1953/4885HDAC3 805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.